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We studied 51 consecutive pediatric patients for the frequency and morbidity of viral in-
fections after liver transplantation. The incidence of primary (67fT/o) and reactivation (480/0) 
Epstein-Barr virus (EBV) infections and reactivation (88fT/o) cytomegalovirus (CMV) in-
fection was comparable to that seen in adult transplant recipients. However, fewer pedi-
atric than adult transplant recipients experienced primary CMV infection (P < .01). Five 
(38%) of 13 CMV infections were symptomatic and included hepatitis, pneumonitis, en-
teritis, and mononucleosis. Two of 14 patients with primary EBV infection subsequently 
developed, at two months and two years after initial infection, an EBV-associated lym-
phoproliferative syndrome, and one of 10 patients with reactivated EBV infection devel-
oped a possible EBV-associated febrile encephalopathy. Other viruses causing infection 
in these children included herpes simplex virus, varicella-zoster virus, adenovirus, parain-
fluenza virus, respiratory syncytial virus, and rotavirus. 
Both Epstein-Barr virus (EBV) and cytomegalovi-
rus (CMV) are notable for their ubiquity, latency, 
and tendency to reactivate in the immunosuppressed 
host. Reports on the frequency and morbidity of 
EBV and CMV infections in adult transplant recipi-
ents from this center are available [1-3]. Compara-
ble data in children have not been reported because, 
until recently, they had not undergone transplanta-
tions in large numbers. The behavior of EBV and 
CMV in pediatric transplant recipients is of interest 
not only because children may respond differently, 
but unlike adults, a large proportion of children have 
not been infected by these viruses before transplan-
tation. Hence, a smaller number of children are at 
risk of developing reactivation infections; however, 
a greater number may be susceptible to primary in-
fections and their consequent morbidity. 
Received for publication 17 November 1986, and in revised fonn 
l3 March 1987. 
This work was supported in part by grant AI-19377 from the 
National Institute of Allergy and Infectious Diseases. 
We thank Laurel Williams. Jill Greve, Kathy Kulka, Lucille 
Guevarra, and Richard DiBiasio for technical assistance; Dr. R. 
Wayne Atchison for performing the assays for IgM to EBV and 
antibody to EBNA; Dr. Ronald Jaffe for pathological descrip-
tion; Dr. George Miller for EBV DNA studies in tissue specimens; 
and Drs. J. Stephen Dummer, Donna J. Freeman, Leonard 
Makowka, and Richard H. Michaels for constructive comments. 
Please address requests for reprints to Dr. Monto Ho, A427 
Crabtree Hall, University of Pittsburgh, Pittsburgh, Pennsylva-
nia 15261. 
273 
This study reports EBV, CMV, and other viral in-
fections in 51 children who received transplants at 
Children's Hospital in Pittsburgh within a 12-month 
period. 
Patients and Methods 
Patients. Fifty-one consecutive pediatric trans-
plant patients were followed up to assess infection. 
Fifty patients received liver transplants and one pa-
tient, a liver- and heart-transplant. This was the first 
transplant for all patients except one, who received 
her second transplant. 
Immunosuppression. Intravenous cyclosporine 
was given before surgery and was continued post-
operatively. When the patient was able to take medi-
cations orally, oral cyclosporine was begun in addi-
tion to the intravenous dose. The intravenous 
cyclosporine was tapered and discontinued, and the 
oral dose was adjusted accordingly. Whole-blood lev-
els of cyclosporine were monitored by high-perfor-
mance liquid chromatography (HPLC) or by RIA 
to maintain levels of "'200-300 Ilg/ml (HPLC) or 
800-1,000 llg/ml (RIA). 
Steroids were given preoperatively, usually as a bo-
lus of hydrocortisone or methylprednisolone. On the 
first postoperative day, a cycle of steroids (equiva-
lent to a dose of 100 mg of prednisone) was given 
and decreased each day until a baseline dose of 20 
mg/day was reached. This dose was usually main-
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tained until discharge, when it was further reduced 
to 5-10 mg/day. 
Surveillance. The objectives of surveillance were 
to prospectively identify and diagnose herpesvirus 
infections by isolating virus and by serology, even 
in the absence of clinical abnormalities. Specimens 
for isolation and serology were collected before trans-
plantation (when possible), usually weekly for the 
first four postoperative weeks, biweekly thereafter, 
and when patients returned for six-month follow-
up visits. When recipients did not return for follow-
up visits, letters were sent, and serum specimens were 
obtained by their attending physicians. The mean du-
ration of specimen collection in recipients who were 
evaluated for viral infection was 309 days, with a 
range of 91-553 days. 
Throat swabs, urine samples, and blood buffy 
coats were obtained routinely for isolating CMV and 
herpes simplex virus (HSV). Specimens were inocu-
lated into tube cultures of human foreskin fibro-
blasts, African green monkey kidney (AGMK) cells, 
and HEp-2 cells. Viruses were identified by their 
characteristic CPE and by host cell range. Throat 
swabs were also used for isolating EBV by transfor-
mation of umbilical cord blood lymphocytes [4]. 
Other viruses were isolated from specimens ordered 
when clinically indicated or were noted incidentally 
from throat or urine cultures. Specimens suspected 
of containing adenovirus or parainfluenza virus were 
inoculated into tube cultures of AGMK, HEp-2, 
Rhesus monkey kidney, and WI-38 cells. Viruses were 
identified presumptively by characteristic CPE or by 
hemadsorptioll and were sent to the Allegheny 
County Diagnostic Laboratories (Pittsburgh) for 
confirmation and typing. All cell cultures were ob-
tained from commercial suppliers (M.A. Bio-
products, Walkersville, Md; and Flow Laboratories, 
McLean, Va). Respiratory syncytial virus was iden-
tified by using the Ortho RSV antigen ELISA test 
(Ortho Diagnostics Systems, Raritan, NJ), and rota-
virus was identified using the ootazyme~ II ELISA 
test (Abbott Diagnostic, North Chicago, Ill). 
Serum or plasma specimens were tested for IgG 
antibody to EBV capsid antigen (VCA) and early an-
tigen (EA) as previously described [5], for antibody 
to CMV by using the anticomplement immunoflu-
orescence test [6J or the FIAX® test (International 
Diagnostic Technology, Santa Clara, Calif), and for 
antibody to HSV by using the neutralization test [7] 
or the FlAX test. Selected serum or plasma speci-
mens were also tested for IgM antibody to VCA and 
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antibody to Epstein-Barr nuclear antigen (EBNA), 
as previously described [5]. Thmor tissue specimens 
were tested for their EBV genome content or EBNA 
by Dr. George Miller (Yale University), as previously 
described [5J. 
Injection. A primary infection was diagnosed by 
a conversion from seronegativity to seropositivity, 
and a reactivation intection ,was diagnosed by a four-
fold or greater increase in titer. The isolation of vi-
rus from a seropositive recipient, in the absence of 
a fourfold or greater increase in antibody titer, was 
defined as asymptomatic shedding. 
Serological data. To distinguish between primary 
and reactivation infections diagnosed during the 
period of follow-up after transplantation, we had to 
know the patient's serological state before infection, 
i.e., before transplantation. A pretransplant serum 
sample was therefore important for this study. This 
sample was available for 7511/0 of the participants (38 
of 51). When such sera were not available, a sample 
obtained during or immediately after transplanta-
tion was tested. Under these circumstances, however, 
passively transferred antibody from the large num-
ber of units of transfused blood products could ob-
scure the true serological status of the recipients This 
occurrence was particularly evident in the case of 
antibody to EBV. If, however, the titer of antibody 
to VCA became negative after it had been positive, 
a primary infection that occurred after transplanta-
tion could still be diagnosed. Fourteen patients 
whose posttransplantation titers of IgG to EBV were 
VCA positive later reverted to seronegativity. In the 
absence of such reversion, the distinction between 
primary and reactivation infection was difficult and 
required the use of ancillary clinical and laboratory 
data, e.g., antibody to EBNA, IgM to VCA, and cul-
tures of virus. 
Clinical follow-up. To obtain the clinical corre-
lates of laboratory findings, one of us (B. Z.) re-
viewed the clinical courses of all patients. Symptom-
atic viral infections were suspected by the constant 
or intermittent presence of fever >38 C for at least 
one week if no other cause, such as other microbial 
infections or rejection, could be found. In addition 
to laboratory evidence of EBV or CMV infection, 
at least one of the following findings was required: 
(l) leukopenia (white blood cells, <4,000); (2) throm-
bocytopenia (platelets, <100,000); (3) atypicallym-
phocytes, >3%; and (4) tissue evidence of local vi-
ral infection, such as isolation of virus from the liver 
or lung or histological evidence of such infection. 
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Viral Infections after Transplantation 
Patients with fever and one or more of the first three 
signs were considered to have the "mononucleosis" 
syndrome. 
Statistics. Differences between means were com-
pared by using Student's t test. Observed proportions 
were compared by using the x,2 test. 
Results 
Patients. Our study population included 23 boys 
and 28 girls. Their ages at transplantation ranged 
from 9 to 179 months, with a mean age of 64 months. 
The majority of patients (32 of 51) had a pretrans-
plantation diagnosis of biliary atresia/hypoplasia, 
and the remainder had a diverse group of diagnoses. 
EBV injection. Forty-two patients had sufficient 
serological and/or virological data to be evaluated 
for EBV infection. Twenty-one (50070) had antibody 
to EBV before transplantation. Three (140/0) of 21 
swabs obtained from seropositive patients before sur-
gery were positive for EBV. These patients were as-
sumed to be asymptomatic shedders. A total of 223 
throat swabs were obtained during follow-up, and 
55 (25%) were positive for EBV. In no case was EBV 
cultured from a subject who remained seronegative. 
Fourteen (67070) of the 21 seronegative recipients 
developed primary EBV infection (table 1). Eight ex-
perienced their infection in the hospital or shortly 
thereafter and hence, the mean day of onset was read-
ily ascertainable (66 ± 10 days after transplantation). 
EBV was isolated from six of these eight patients. 
Two patients had symptoms attributable to EBV 
infection. 
One patient was undergoing a primary EBV in-
fection at the time of transplantation and, two 
months later, became symptomatic, with fever, ton-
sillitis, and lymphadenopathy. Th¢tonsillar tissue 
showed monomorphorous polyclonallymphoprolif-
eration and contained EBV DNA by hybridization. 
A right inguinal lymph node was positive for EBNA 
by immunofluorescent staining. This patient is well 
2.5 years after the initial infection. 
One month after transplantation, another patient 
experienced a primary EBV infection associated with 
exudative pharyngitis and atypical lymphocytes. TWo 
years later, when he was admitted with a history of 
rectal bleeding and abdominal pain of three-weeks' 
duration, a perforated cecum secondary to a lym-
phoma and mesenteric mass was found. This find-
ing was characterized by a monomorphous, ma-
lignant-appearing, diffuse lymphoproliferative 
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Table 1. EBV and CMV infections in pediatric trans-
plant recipients. 
No. of 
Pretransplant No. with symptomatic 
serological No. of infectionl patientsl 
status patients total no. (070) total no. (Olo) 
Negative for EBV 21 14121 (67) 2114 (14) 
Positive for EBV 21 10/21 (48) 1/10 (10) 
Negative for CMV 35 6/35 (17) 3/6 (50) 
Positive for CMV 8 7/8 (88) 217 (29) 
infiltration in all layers of the small bowel. Immuno-
peroxidase staining revealed monoclonal A-light-
chain-producing B cells. EBNA and EBV DNA were 
found in a specimen of the tumor. The tumor re-
gressed after reduction of immunosuppression [8]. 
Twenty-one recipients had antibodies to EBV be-
fore transplantation. Ten (48%) developed serolog-
ical evidence of reactivation infection (table 1). Five 
of the 10 were also found to shed EBV in the throat. 
The time of reactivation could be accurately dated 
in seven patients because reactivation occurred dur-
ing hospitalization (61 ± 11 days after transplanta-
tion). Eleven of the 21 patients had no serological 
evidence of reactivation after transplantation; 8 pa-
tients shed EBV asymptomatically. To date, only one 
of the initially seropositive patients has developed 
possible EBV-associated pathology. This patient had 
an asymptomatic, reactivated EBV infection that was 
diagnosed by elevated levels of antibody to VCA 52 
days after transplantation. About two years later she 
was admitted with a febrile encephalopathy and titers 
of IgG antibody to VCA (>1,280) and EA (>80). 
These titers are unusually high for our patients and 
indicate possible active, chronic infection. No tissue 
was available for EBV studies. Thus, in this case, 
there is a presumptive, but not proven, association 
between the encephalopathy and EBV infection. 
In summary, 24 (57%) of 42 patients developed 
EBV infection, and three (12070) were symptomatic. 
CMV injection. Forty-three patients had suffi-
cient serological and/or virological data to be evalu-
ated for CMV infection, and eight (19%) had anti-
body to CMV before transplantation (table 1). Only 
one throat swab of 24 blood buffy coat, urine, and 
throat swab specimens obtained from seropositive 
patients before surgery was positive for CMV. The 
throat swab was from a patient who had serological 
evidence of CMV reactivation infection between 
seven and 21 days after transplantation. Asymptom-
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atic shedding of CMV, unlike EBV, is rare before 
transplantation. 
A total of 779 specimens, consisting of throat 
swabs, urine specimens, and blood buffy coats, was 
obtained during follow-up after transplantation; 74 
(9.50,70) were positive. CMV was recovered more fre-
quently from urine cultures and throat swabs than 
from blood buffy coats. Thirty-four (13.70,70) of 248 
urine cultures were positive, and 32 (13.20,70) of 242 
throat swabs were positive; only 8 (2.80,70) of 289 
blood buffy coats were positive. In this pediatric 
population, as in the adult transplant population [1], 
isolation of CMV was diagnostic for infection; CMV 
was isolated from 12 patients during follow-up, and 
all patients had either primary infection or reacti-
vation infection, as determined by serological 
criteria. Of these 12 patients, 3 were positive from 
one site only (all urine cultures), 6 were positive from 
two sites (all urine and throat), and 3 were positive 
from all three sites. One patient experienced her pri-
mary infection after discharge from the hospital, 
when samples for culture were not available, and di-
agnosis was made on the basis of serological changes 
only. 
Six (17U70) of the 35 seronegative recipients devel-
. oped primary CMV infection (table 1). Five experi-
enced a primary infection during their initial hospi-
talization (mean, 26 ± 6 days after transplantation). 
Three patients had symptoms associated with CMV 
infection. 
The first patient had a primary CMV infection 
about the time of transplantation and had a post-
operative course marked by fever and abdominal dis-
tension leading to laparotomy 16 days after trans-
plantation. A perforation in the Roux-en-Y limb, 
along with mucosal ulcers, was found. CMV inclu-
sions were found in the ulcer crater. He ultimately 
recovered from the CMV enteritis without an alter-
ation of his immunosuppression regimen. In the sec-
ond patient, CMV infection was associated with hep-
atitis, interstitial pneumonitis, and esophagitis, and 
the viral inclusions were found in these three respec-
tive anatomic sites. She was treated by temporarily 
stopping her cyclosporine; she eventually recovered. 
The third patient had the typical picture of CMV 
mononucleosis, including fever, leukopenia, and 
atypical lymphocytes. He recovered without a reduc-
tion in immunosuppression. 
Eight recipients had antibody to CMV before 
transplantation, and seven (880,70) had reactivation 
infection (table 1). The mean time of onset of reac-
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tivation infection was 37 ± 10 days after transplan-
tation. Two patients had disease attributable to reac-
tivation infection. One patient received a second liver 
transplant because of initial-graft failure due to a 
thrombosed hepatic artery. Persistent fever and pul-
monary infiltrates prompted a laparotomy, during 
which a mycotic aneurysm of the aortic graft rup-
tured, and the patient died. Necropsy demonstrated 
CMV inclusions in the second hepatic allograft. This 
represents a case of CMV hepatitis in the second allo-
graft that was undiagnosed antemortem. The sec-
ond patient had a mononucleosis syndrome associ-
ated with fever, a macular erythematous rash on his 
chest, and leukopenia. The rash became petechial 
despite a normal platelet count. He recovered 
spontaneously. 
In summary, 13 (30U70) of 43 patients had CMV 
infection, and five (38070) had CMV-associated 
disease. 
Other herpesvirus injection~K Seven recipients 
had herpetic lesions that were confirmed by isolat-
ing HSV. All of the recipients had reactivated infec-
tions because the patients had antibodies to HSV 
before transplantation. Two patients had lip lesions, 
and five had mouth and/or tongue lesions; the mean 
time of appearance was 22 days after transplanta-
tion. 1\vo patients also experienced fever during the 
appearance of their lesions. All patients were treated 
intravenously with acyclovir, and all recovered un-
eventfully. 
Three patients developed varicella, which was di-
agnosed clinically. One recipient had vesicular lesions 
on her trunk "-'22 days after transplantation. A 
Tzanck preparation of the lesions showed mul-
tinucleated giant cells, but no virus was recovered 
from the vesicle fluid. She was treated with acyclovir 
for 10 days and recovered uneventfully. The second 
patient had an attack of varicella "-'1.5 years after 
transplantation, was treated with acyclovir, and re-
covered uneventfully. The third patient was dis-
charged 27 days after transplantation and had no 
subsequent laboratory or clinical follow-up until 137 
days after transplantation, when an autopsy was per-
formed after she died of disseminated varicella. 
Other viral injections. Stool specimens to be 
tested for rotavirus were only obtained when clini-
cally indicated. Twenty-one specimens were taken 
from 14 patients, and two patients (14U70) were posi-
tive once. Both positive specimens were obtained 24 
days after transplantation. Both patients had diar-
rhea, an increase in levels of serum aspartate ami-
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notransferase, and were treated for rejection. One 
patient developed progressive rejection and received 
a second transplant; the graft of the other patient 
survived. It is possible that diarrhea caused by 
rotavirus infection led to cyclosporine malabsorp-
tion, which may have been a factor contributing to 
rejection. 
Adenovirus was isolated from four patients, and 
from one of these four, respiratory syncytial virus 
and parainfluenza virus were also isolated. Ascrib-
ing particular signs or symptoms to infection with 
these viruses was not easy because of other infec-
tious complications that occurred after transplan-
tation. Of three of the four patients from whom 
adenovirus was isolated, one was febrile, had nodu-
lar pulmonary infIltrates, and was experiencing a pri-
mary CMV infection when adenovirus (not typed) 
was isolated from his throat. Another patient was 
undergoing primary CMV infection when adenovi-
rus 5 was isolated from buffy coats, urine specimens, 
and a liver biopsy specimeI!, which histologically 
showed granulomatous necrosis. The third patient 
was afebrile when adenovirus 2 was isolated from her 
throat. The fourth patient was febrile, had tachyp-
nea and wheezing when parainfluenza was isolated 
from her throat, and had no respiratory symptoms 
when respiratory syncytial virus was isolated from 
her throat. She was febrile, had cholangitis, and 
pneumocystis pneumonia when adenovirus 2 was iso-
lated from her throat and urine. 
Discussion 
The purpose of this study was to determine the im-
portance of viral infections in pediatric liver trans-
plant recipients. Viral infections, particularly her-
pesvirus infections, occur frequently after organ 
transplantation. The herpesvirus infections of spe-
cial interest were those caused by EBV and CMV [I}. 
Twenty-four (570/0) of 42 pediatric liver recipients 
had evidence of EBV infection. This incidence of 
EBV infection is significantly higher (P = .03) than 
that seen in adult transplant recipients, in whom 51 
(36%) of 140 recipients had EBV infection [authors' 
unpublished observations; 5}. These rates for EBV 
infection in recipients immunosuppressed with cy-
closporine are similar to the 34% reported by others 
in renal transplant recipients [9] and to our own 
previous work [10], in which 32 % of renal transplant 
patients receiving azathioprine and prednisone de-
veloped EBV infection. Our experience with adult 
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transplant recipients receiving cyclosporine suggests 
that the frequency of EBV infection varies: heart and 
heart-lung recipients have the highest frequency, fol-
lowed by liver recipients; kidney recipients have the 
lowest frequency. 
The main difference between adult and pediatric 
recipients is the greater proportion of children who 
were seronegative for EBV before transplantation. 
Fifty percent of children were seronegative, whereas 
only 8% of adults were seronegative. The propor-
tion of children who developed primary EBV infec-
tion after transplantation (67%), however, is simi-
lar to the proportion of adult recipients who 
developed primary infection (82 %). There is also no 
significant difference between the proportions of 
pediatric (48%) and adult (33 %) recipients who de-
veloped reactivation infection. The proportion of 
pediatric patients seropositive for EBV who excreted 
the virus in oral secretions after transplantation (13 
[65%] of 20) is comparable to those (50%-800/0) 
noted in previous studies [11-13] on renal transplant 
recipients. 
Morbidity due to EBV infection after transplan-
tation has not been as well defined as morbidity due 
to CMV infection. In reality, it is often diffIcult to 
specifIcally ascribe symptoms to either EBV or CMV, 
particularly when patients are experiencing EBV and 
CMV infections concomitantly or within a few weeks 
of each other, as was often the case in our pediatric 
population. Two patients who developed primary 
EBV infection, however, had symptoms specifically 
attributable to EBV. In both cases there was evidence 
of the presence of EBNA or EBV DNA in lym-
phoproliferati ve lesions. 
Although small, this series of patients demon-
_ strates a wide diversity of syndromes possibly related 
to EBV infection. In one case, a mononucleosis syn-
drome occurred two months after laboratory evi-
dence of a primary infection; in the other, there was 
no evidence of a viral, mononucleosis-like syndrome 
at all, but two years after a primary infection, the 
patient developed an intestinal lymphoma with tis-
sue evidence of EBV activity. A series of such lym-
phomas have been described in adults [5]. Most, but 
not all, such tumors were associated with a prior 
mononucleosis-like "viral syndrome." An important 
point in that study was that patients with primary 
infections were at higher risk for developing EBV-
related lymphomas and lymphoproliferative syn-
dromes. This finding is consistent with those in this 
study. 
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A different syndrome was observed in a patient 
who had an asymptomatic reactivation infection af-
ter transplantation, but who, two years later, still had 
serological evidence of an active, chronic EBV in-
fection and who developed a febrile encephalopa-
thy. Seizures and meningoencephalitis complicating 
EBV mononucleosis acquired during childhood have 
previously been described [14]. The encephalopathy 
in this case could not be unequivocally ascribed to 
EBV because we had no tissue evidence. It is appar-
ent that in searching for morbidity due to EBV in-
fections, one must also look for late and indirect ef-
fects. 
Thirteen (30OJo) of 43 pediatric liver recipients had 
evidence of CMV infection, a frequency that is sig-
nificantly lower than the frequency of CMV infec-
tion in adult recipients (70 [77OJo] of91; P = <.00001) 
[2]. This difference is due to the high proportion of 
seronegative pediatric patients (35 [81OJo] of 43) and 
to the low incidence of primary CMV infection (six 
[17OJo] of 35). By comparison, only 21OJo (19 of 91) 
of adult recipients are seronegative, and the serocon-
version rate is significantly higher (11 [58OJo 1 of 19; 
P = .006). The frequency of CMV reactivation in-
fection, however, does not differ between pediatric 
(seven [88OJo] of eight) and adult (59 [82OJo] of 72) 
recipients [2]. As is the case in adult transplant 
recipients [1], more patients with primary CMV in-
fection were symptomatic than were those with reac-
tivation infections, although the numbers were small. 
The risk of acquiring primary EBV or CMV in-
fection, i.e., acquiring infection de novo after trans-
plantation, was 67OJo (14 of 21) in the case of EBV 
and 17OJo (six of 35) in the case of CMV. Tho impor-
tant possible sources of CMV infection have previ-
ously been identified in organ transplantation in 
adults - transmission of the virus by the donated or-
gan or by blood and blood products [1, 15]. Neither 
source has been documented for EBV infection. In 
view of the fact that there is evidence of EBV trans-
mission by transfusion [16], however, it would not 
be unreasonable to assume that these two sources 
may also be important in the case of EBV. 
There was no difference in the mean number of 
units of blood products received by those patients 
who acquired either primary EBV or primary CMV 
infection when compared with those who did not ac-
quire infection. Nor have we seen any correlation of 
donor seropositivity to EBV with subsequent devel-
opment of EBV infection in recipients. One com-
plicating factor, vitiating the significance of this find-
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ing, is that donors are transfused intraoperatively 
during harvest of the liver. We also asked whether 
passively transfused antibody might protect against 
infection. Passively transfused IgG antibody to EBV 
VCA was noted after transplantation in all 21 pa-
tients who were seronegative to EBV before trans-
plantation. There was no difference, however, in ei-
ther the duration or the titer of transfused antibody 
when comparing those who acquired EBV infection 
with those who did not. 
There were 35 recipients who were seronegative for 
CMV. Only three seropositive donors were detected 
among the available donor sera. One donated to a 
subsequently infected recipient, and two donated to 
recipients who did not become infected with CMV. 
The relatively low rate of acquiring primary CMV 
infection (17OJo), compared with the experience in 
adult organ transplantation (58OJo),might be related 
to the high proportion of pediatric donors who were 
seronegative. 
Adenovirus was isolated from four patients (9OJo ); 
this incidence is not significantly different from that 
of 4.9OJo noted in bone marrow transplant recipients 
[17]. Three of the four patients had symptoms, in-
cluding fever, when adenovirus was isolated. In two 
patients, however, the relation between symptoms 
due to other infections and to adenovirus was not 
clear. One patient did, however, have an invasive in-
fection, as demonstrated by recovery of adenovirus 
from her liver at biopsy. 
In this study, the prevalence of other viral infec-
tions, e.g., those caused by rotavirus and adenovi-
rus, may be an underestimate of the true prevalence,. 
because of the lack of routine periodic cultures. 
However, this study reemphasizes the fact that her-
pesvirus infections, particularly those caused by EBV 
and CMV and many of which are not clinically ap-
parent, can be documented by routine periodic cul-
tures and by serological studies. 
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